C12N 2760/12171
Demonstrated in vivo effect
C12N2760/12171 (Demonstrated in vivo effect) appears on 7 US grants and 9 published applications in this corpus.
Search patents in C12N- Granted patents
- 7
- Published applications
- 9
- Assignees
- 8
- Inventors
- 4
- Latest grant
- 27 Jan 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2014 | 0 | 1 |
| 2015 | 0 | 0 |
| 2016 | 1 | 2 |
| 2017 | 1 | 1 |
| 2018 | 1 | 1 |
| 2019 | 2 | 0 |
| 2020 | 0 | 2 |
| 2021 | 1 | 0 |
| 2022 | 0 | 1 |
| 2023 | 0 | 1 |
| 2024 | 0 | 0 |
| 2025 | 0 | 0 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Nucleic acid vaccine composition comprising a lipid formulation, and method of increasing the potency of nucleic acid vaccines27 Jan 2026US 12,533,410 B2Arcturus Therapeutics, Inc.
- Sin Nombre virus full-length M segment-based DNA vaccines26 Oct 2021US 11,155,834 B2The Government of the United States, as represented by the Secretary of the Army
- Gene optimized Hantaan virus M segment DNA vaccine for hemorrhagic fever with renal syndrome3 Dec 2019US 10,493,142 B2
- Sin Nombre virus full-length M segment-based DNA vaccines15 Oct 2019US 10,443,073 B2The Government of the United States, as represented by the Secretary of the Army
- Gene optimized hantaan virus M segment DNA vaccine for hemorrhagic fever with renal syndrome15 May 2018US 9,968,669 B2The United States of America as represented by the Secretary of the Army
- Nucleic Acid Vaccine Composition Comprising a Lipid Formulation, and Method of Increasing the Potency of Nucleic Acid Vaccines7 Dec 2023US 2023/0390389 A1Arcturus Therapeutics, Inc.
- Sin nombre virus full-length m segment-based dna vaccines24 Mar 2022US 2022/0090136 A1The Government of the United States, as represented by the Secretary of the Army
- Sin nombre virus full-length m segment-based dna vaccines2 Apr 2020US 2020/0102576 A1The Government of the United States, as represented by the Secretary of the Army
- Nucleic acid vaccine composition comprising a lipid formulation, and method of increasing the potency of nucleic acid vaccines13 Feb 2020US 2020/0046830 A1Arcturus Therapeutics, Inc.
- Gene Optimized Hantaan Virus M Segment DNA Vaccine For Hemorrhagic Fever With Renal Syndrome4 Oct 2018US 2018/0280495 A1The Government of the United States, as represented by the Secretary of the Army
Most cited
By later US patents
No patent in this class has been cited by a later US patent yet.